Circumventing Resistance to EGFR-Targeted Therapy in Glioblastoma

Wiskerke, D

Publication date

August 2022

Abstract

Glioblastoma (GBM) is the most aggressive form of adult brain cancer with a 5-year survival rate of <5%. In over 15 years, GBM has not seen an improvement in overall survival and therapy options despite extensive research efforts. With standard therapy of radiotherapy and chemotherapy with temozolomide (TMZ), patients often relapse within less than a year. EGFR is amplified in ~50% of patients diagnosed with primary glioblastoma (GBM) and has been a main focus for research into targeted therapy. Thus far, EGFR tyrosine kinase inhibitors (TKIs) and (drug/toxin-conjugated) antibodies (ADCs) have been in clinical trials for and recurrent GBM (rGBM) patients but these have been unsuccessful. My project aims to investigate resistance to EGFR tar...

Extracted data

We use cookies to provide a better user experience.

Data Protection

Circumventing Resistance to EGFR-Targeted Therapy in Glioblastoma

Abstract

Extracted data

Circumventing Resistance to EGFR-Targeted Therapy in Glioblastoma

Abstract

Extracted data

Related items

Related items